Dabigatran ( DrugBank: Dabigatran )

---

5 diseases

ID	Disease name (Link within this page)	Number of trials
51	Scleroderma	1
75	Cushing disease	1
85	Idiopathic interstitial pneumonia	1
91	Budd-Chiari syndrome	1
124	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy	1

51. Scleroderma

---

Clinical trials : 525 /  Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02426229 (ClinicalTrials.gov)	February 2016	4/3/2015	Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma	Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma	Scleroderma;Interstitial Lung Disease	Drug: dabigatran etexilate	Medical University of South Carolina	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	18 Years	70 Years	All	15	Phase 1	United States

75. Cushing disease

---

Clinical trials : 205 /  Drugs : 176 - (DrugBank : 45) / Drug target genes : 61 - Drug target pathways : 127

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05347979 (ClinicalTrials.gov)	May 25, 2022	18/4/2022	Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants	An Open-Label, Drug-Drug Interaction Study Designed to Evaluate the Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Subjects	Cushing Syndrome;Neoplasms	Drug: Dabigatran Etexilate;Drug: Relacorilant	Corcept Therapeutics	NULL	Completed	18 Years	55 Years	All	30	Phase 1	United States

85. Idiopathic interstitial pneumonia

---

Clinical trials : 627 /  Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02885961 (ClinicalTrials.gov)	August 2016	15/8/2016	The Coagulation Cascade in Idiopathic Pulmonary Fibrosis	Investigating the Role of the Coagulation Cascade in Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis;IPF;Interstitial Lung Disease	Drug: Dabigatran;Radiation: FDG PET scan	University College, London	NULL	Not yet recruiting	40 Years	80 Years	Both	12	N/A	NULL

91. Budd-Chiari syndrome

---

Clinical trials : 4 /  Drugs : 5 - (DrugBank : 4) / Drug target genes : 4 - Drug target pathways : 14

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000015319	2012/06/01	12/10/2014	The efficacy of dabigatran for portal vein thrombosis/Budd-Chiari syndrome	The efficacy of dabigatran for portal vein thrombosis/Budd-Chiari syndrome - The efficacy of dabigatran for portal vein thrombosis/Budd-Chiari syndrome	Portal vein thrombosis or Budd-Chiari syndrome	dabigatran	Chiba University Graduate School of Medicine, Department of Gastroenterology and Nephrology	NULL	Recruiting	20years-old	70years-old	Male and Female	20	Not selected	Japan

124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy

---

Clinical trials : 12 /  Drugs : 14 - (DrugBank : 5) / Drug target genes : 3 - Drug target pathways : 11

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01361763 (ClinicalTrials.gov)	June 2011	16/5/2011	Safety Study of Dabigatran in CADASIL	Phase II, Randomized, Crossover, Single Blind, Safety Trial of DABIGATRAN Versus ASA for Preventing Ischaemic Brain Lesions in Patients Affected by CADASIL	CADASIL	Drug: Dabigatran;Drug: Antiplatelets	S. Andrea Hospital	NULL	Recruiting	18 Years	N/A	Both	50	Phase 2	Italy

Back to top